sfj pharmaceuticals inc
SFJ Pharma To Conduct Phase III Trial Of Pfizer’s Axitinib Adjuvant Treatment In Asia
SFJ Pharma Ltd. will conduct a Phase III clinical trial in Asia of Pfizer’s axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.



